These mechanism likelycontribute to the “class effect” of PI3Kδ (Brown et al. 2014; Furman et al. 2014), BTK (Byrd et al. 2013), and SYK inhibitors (Friedberg et al. 2010) in CLL and MCL patients (Chang et al.2013), where a mobilizing effect(“redistribution”) of tissue-resident B cells into the peripheral bloodcharacteristically is seen during the first months of therapy (Burger and Montserrat2013). The gene discussed is SYK; the disease is B-cell chronic lymphocytic leukemia.